Generic Cosopt and Trusopt available now

Article

Generic versions of dorzolamide-timolol (Cosopt) and dorzolamide hydrochloride (Trusopt; Merck) are now available from Prasco.

Generic versions of Merck's dorzolamide-timolol (Cosopt) and dorzolamide hydrochloride (Trusopt; Merck) are now being marketed in the US by Prasco Laboratories, under licence from Merck.

Prasco has released a statement detailing the therapeutic equivalence of its generic versions to Merck's branded drugs. As with the branded versions, the generic formulations are contained within the Ocumeter Plus dispensing container.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Related Content
European Union flags outside the European Commission, where the Alcon Clareon Vivity IOL received a CE mark. Image credit: ©Arcady – stock.adobe.com

Alcon Clareon Vivity IOL receives CE mark, European commercialisation announced

Hattie Hayes
March 25th 2025
Article

The lens will be available with the Monarch IV manual delivery system in Q2 and the AutonoMe Automated Pre-Loaded Delivery System in Q3

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
Two boxes, labeled "yes" and "no." There is a red checkmark in the "no" box. Concept portraying an ophthalmic clinical trial which does not meet its endpoint. Image credit: ©Matthew Benoit – stock.adobe.com

Phase 3 COAST trial fails to meet primary endpoints for wet AMD, Opthea reports

Martin David Harp
March 24th 2025
Article

The Combination OPT-302 with Aflibercept Study (COAST) evaluated sozinibercept 2 mg in combination with aflibercept 2 mg for wet age-related macular degeneration

Rows of medical syringes in sanitary packaging. Concept image for aflibercept intravitreal eye injection. ©Titolino – stock.adobe.com

Study examines real-world treat-and-extend outcomes and background factors of macular atrophy

Lynda Charters
March 21st 2025
Article

The study demonstrated that the number of injections needed gradually decreased during the follow-up period

A young girl wearing glasses looks at a laptop, perhaps while attending online school. Concept image for COVID-19 and paediatric astigmatism. Image credit: ©Mangostar – stock.adobe.com

Increased paediatric astigmatism prevalence and severity after COVID-19

Lynda Charters
March 21st 2025
Article

The study findings indicated that lifestyle changes associated with the COVID-19 pandemic were connected to an increase in childhood astigmatisms

A blue hazard sign, an exclamation point (!) inside a triangle, to communicate the risks of misdiagnosing geographic atrophy and age-related macular degeneration. Image credit: ©jcsnb – stock.adobe.com

Researchers raise awareness of macular pathologies which mimic AMD and GA

Lynda Charters
March 20th 2025
Article

Inherited retinal diseases have disease processes distinct from age-related macular degeneration and geographic atrophy, but may present with "phenocopy" clinical signs

© 2025 MJH Life Sciences

All rights reserved.